TG Therapeutics reported $754.37M in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 57.3B 19M Jun/2026
Ardelyx USD 256.19M 47.93M Jun/2026
Arrowhead Research USD 983.69M 5.77M Jun/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 7.69B 398.3M Sep/2026
Corcept Therapeutics USD 8.99M 430K Sep/2026
Curis USD 0 0 Jun/2022
Gilead Sciences USD 26.25B 4.07B Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
TG Therapeutics USD 754.37M 68K Sep/2026
Verastem USD 66.79M 26.7M Sep/2024
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026